Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Brilaroxazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 17/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.98 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.98 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.71 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.71 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.71 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.71 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.71 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.71 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.71 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.71 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.71 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.71 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.71 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.71 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.71 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brilaroxazine SCHEMBL31038584 | 1.00 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Brilaroxazine SCHEMBL29368394 | 0.99 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Brilaroxazine SCHEMBL30999087 | 0.99 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Brilaroxazine SCHEMBL30900936 | 0.99 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Brilaroxazine SCHEMBL3404085 | 0.99 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| SCHEMBL8160207 | 0.85 | DRD2 (0.80) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Hydrochloric Acid SCHEMBL31038578 | 0.84 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Hydrochloric Acid SCHEMBL3404095 | 0.84 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Aripiprazole SCHEMBL29935430 | 0.84 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Aripiprazole SCHEMBL8044 | 0.84 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR2BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9907803-B2 | Methods for treating attention deficit hyperactivity disorder | REVIVA PHARMACEUTICALS, INC. (US) | 2018-03-06 | — | — | US | claimed |
| US-20170035772-A1 | METHODS FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | REVIVA PHARMACEUTICALS INC (US) | 2017-02-09 | — | — | US | claimed |
| US-12053477-B2 | Methods for treating pulmonary fibrosis | REVIVA PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-3244896-B1 | METHODS FOR TREATING PULMONARY HYPERTENSION | REVIVA PHARMACEUTICALS INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | REVIVA PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20210128570-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | REVIVA PHARMACEUTICALS INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-10441590-B2 | Methods for treating pulmonary hypertension | REVIVA PHARMACEUTICALS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-9975862-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180125851-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | REVIVA PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180071299-A1 | METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE | REVIVA PHARMACEUTICALS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071298-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | REVIVA PHARMACEUTICALS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20150005298-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2015-01-01 | — | — | US | disclosed |
| US-8859552-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140155392-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8461154-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8431570-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120220574-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | BHAT LAXMINARAYAN (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220579-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | BHAT LAXMINARAYAN (US) | 2012-08-30 | — | — | US | disclosed |
| US-8188076-B2 | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128570-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-20180071298-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN1, PSEN2, APP | DRD2 380/4885HTR1A 39/4885HTR2A 18/4885 |
| US-20180125851-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | CYP11B2, PAH, CYP11B1 | DRD2 3542/4885HTR1A 453/4885HTR2A 541/4885 |
| US-20150005298-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | GRIK5, HTR5A, HTR2A | DRD2 10/4885HTR1A 32/4885HTR2A 3/4885 |
| US-20120220579-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | DRD2 14/4885HTR1A 22/4885HTR2A 3/4885 |
| US-20180071299-A1 | METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE | PARK7, SNCA, COMT | DRD2 87/4885HTR1A 27/4885HTR2A 33/4885 |
| US-20120220574-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | DRD2 14/4885HTR1A 22/4885HTR2A 3/4885 |
| US-20140155392-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | DRD2 14/4885HTR1A 22/4885HTR2A 3/4885 |
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-12053477-B2 | Methods for treating pulmonary fibrosis | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-20170035772-A1 | METHODS FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | HTR2C, SLC6A2, HTR5A | DRD2 36/4885HTR1A 12/4885HTR2A 6/4885 |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | GRIK5, HTR5A, KYNU | DRD2 18/4885HTR1A 33/4885HTR2A 5/4885 |
| US-10441590-B2 | Methods for treating pulmonary hypertension | CYP11B2, PAH, CYP11B1 | DRD2 3542/4885HTR1A 453/4885HTR2A 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.